CTT PHARMACEUTICAL HOLDINGS, INC. financial statements
Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data CTT PHARMACEUTICAL HOLDINGS, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2011
FY2011
FY2012
FY2013
FY2014
Selling and marketing
0.13
General and administrative
0.31
0.32
0.16
0
0.02
Operating expenses
2.07
0.76
1.19
0.02
0.67
Operating income
-2.07
-0.76
-1.19
-0.02
-0.67
Net income to minority interests
-0.5
0
Net income
-1.1
3.74
-1
-0.02
-0.67
EBITDA
-2
-0.76
EPS, basic
-0.13
0.42
-0.11
0.01
-0.04
EPS, diluted
-0.13
0.40
-0.11
0.01
-0.04
Shares, basic (weighted)
8.47
8.92
9.41
9.41
16.3
Shares, diluted (weighted)
8.47
9.49
9.41
9.41
16.3
Balance sheet
FY2011
FY2011
FY2012
FY2013
FY2014
Cash and equivalents
0.05
0.57
0
0
0.08
Short-term investments
0
0.16
0
Receivables
0.17
0
0.01
0
0.01
Other current assets
0.17
0.04
0.02
0
0.96
Total current assets
0.52
0.75
0.2
0.01
1.05
Property, plant and equipment
0.43
0
Total assets
1.26
4.18
0.2
0
1.66
Accounts payable
0.75
0.45
0.32
0.01
0.02
Total current liabilities
0.94
3.73
0.59
0.25
Total liabilities
1.26
3.73
0.59
0.03
0.17
Paid-in capital
12.2
12.5
12.6
0.08
0.15
Retained earnings
-0.2
-0.87
Other comprehensive income
-0.11
-0.11
0
-0
-0
Shareholders' equity
0
0.46
-0.02
-0.03
1.49
Minority interests
0.32
0
Total equity
0
0.46
-0.02
-0.03
1.49
Total liabilities and equity
1.26
4.18
0.2
0
1.66
Shares outstanding
163
9.3
9.3
14.9
19.5
Cash flow statement
FY2011
FY2011
FY2012
FY2013
FY2014
Net income
-1.1
3.74
-1
-0.02
-0.67
Depreciation and amortization
0.07
0
Stock-based compensation
0.15
0.16
0.04
0
0.31
Change in receivables
-0.16
0
-0.01
0
Change in payables
0.53
0.33
-0.14
0.01
-0.01
Cash from operations
-1.67
-0.32
-1.03
-0
-0.07
Sales and maturities of investments
0
0.26
0.18
Cash from investing
0
0.88
0.44
0.12
0.15
Stock issued
0
0.1
0.03
0
Cash from financing
1.45
-0.04
0.03
0
Exchange rate effect
0
0
Net change in cash
-0.22
0.52
-0.56
-0.01
0.08
Interest paid
0
0
0
0
Income taxes paid
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to September 30, 2015; growth uses fiscal years. Valuation uses the share price of $0.05 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-226.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-180.9%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
EPS growth, 1y
-500.0%
EPS vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
48.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 3y
-26.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
73.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
19.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.01
Cash from operations / diluted weighted shares.
Book value per share
$0.03
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
4.37x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
4.37x
Market cap / tangible book value, when positive.
Earnings yield
-51.7%
Net income / market cap (the inverse of P/E).
Was CTT PHARMACEUTICAL HOLDINGS, INC. profitable in fiscal 2014?
No. It reported a net loss of $672.2K.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.